market access

The latest practical tools and information

Stay up to date

Our market access courses are geared towards employees in market access and public affairs, key account managers, medical advisors, product managers and new managers in the pharma industry. Our Market Access Diploma ensures comprehensive knowledge of the Danish health care system and its funding models, policy makers and patient associations, and is essential for anyone working with market access in the pharma industry. 

  

Read about the programme structure for Market Access

Focused market access courses

The diploma in Medical Market Access offers a range of practical tools that enable you to work strategically with new and established pharma products on the market. You will also learn all the latest information on grant applications, the private health care market and interaction with the public sector. With a diploma in Medical Market Access, you also become eligible for Aalborg University’s Master of Business Administration (MBA).


Courses

Market Access Today and Tomorrow - Read more

Market Access Management and Regulations - Read more

Cross-Functional Market Access - Read more

Securing Market Uptake - Read more  

  

What is QALY?

Quality-adjusted life year (QALY) is an effect measure that combines quality of life and survival. The method is used to measure the overall health gain, i.e. how many good years of life are gained by a new treatment.

When comparing the costs with the effect (QALY), one obtains a cost-effectiveness measure (cost/QALY). The cost-effectiveness demonstrates the cost of a life year gained, in perfect health, for the specific treatment.

The method makes it possible to compare treatments across disease areas, as the effect of all kinds of treatments can be calculated in QALYs. This gives decision makers a basis for prioritisation. The method is internationally accepted as the best possible decision-making fundament for prioritisation in the healthcare system. The Danish Medicines Council has used the method since January 2021.

As part of a pharmaceutical company's application to the Medicines Council for the recommendation of a new drug, the company must calculate the cost effectiveness (cost/QALY).



WANT TO KNOW MORE?

Contact Client Manager Ida Salicath at +45 39 15 09 46

Send me an email